Cholesterol depletion sensitizes gallbladder cancer to cisplatin by impairing DNA damage response

References

• Spann NJ, Glass CK. Sterols and oxysterols in immune cell function. Nat Immunol. 2013;14:893–900.
   PubMed Web of Science ®Google Scholar
• Castellano BM, Thelen AM, Moldavski O, et al. Lysosomal cholesterol activates mTORC1 via an SLC38A9-Niemann-Pick C1 signaling complex. Science. 2017;355:1306–1311.
   PubMed Web of Science ®Google Scholar
• Gong X, Qian H, Zhou X, et al. Structural insights into the Niemann-Pick C1 (NPC1)-mediated cholesterol transfer and Ebola infection. Cell. 2016;165:1467–1478.
   PubMed Web of Science ®Google Scholar
• Pelton K, Freeman MR, Solomon KR. Cholesterol and prostate cancer. Curr Opin Pharmacol. 2012;12:751–759.
   PubMed Web of Science ®Google Scholar
• Jacobs EJ, Stevens VL, Newton CC, et al. Plasma total, LDL, and HDL cholesterol and risk of aggressive prostate cancer in the cancer prevention Study II nutrition cohort. Cancer Causes Control. 2012;23:1289–1296.
   PubMed Web of Science ®Google Scholar
• Shafique K, McLoone P, Qureshi K, et al. Cholesterol and the risk of grade-specific prostate cancer incidence: evidence from two large prospective cohort studies with up to 37 years’ follow up. BMC Cancer. 2012;12:25.
   PubMed Web of Science ®Google Scholar
• Ikonen E. Cellular cholesterol trafficking and compartmentalization. Nat Rev Mol Cell Biol. 2008;9:125–138.
   PubMed Web of Science ®Google Scholar
• Otto CM. Statins for primary prevention of cardiovascular disease. BMJ. 2016;355:i6334.
   PubMedGoogle Scholar
• Baek AE, Yu YA, He S, et al. The cholesterol metabolite 27 hydroxycholesterol facilitates breast cancer metastasis through its actions on immune cells. Nat Commun. 2017;8:864.
   PubMed Web of Science ®Google Scholar
• Perucha E, Melchiotti R, Bibby JA, et al. The cholesterol biosynthesis pathway regulates IL-10 expression in human Th1 cells. Nat Commun. 2019;10:498.
   PubMed Web of Science ®Google Scholar
• Wang Z, Wu Y, Wang H, et al. Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility. Proc Natl Acad Sci U S A. 2014;111:E89–98.
   PubMed Web of Science ®Google Scholar
• Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med. 2012;367:1792–1802.
   PubMed Web of Science ®Google Scholar
• Agopian VG, Hiatt JR. The timing of reoperation for incidental gallbladder cancer: sooner or later? JAMA Surg. 2017;152:149.
   PubMed Web of Science ®Google Scholar
• Kasumova GG, Tabatabaie O, Najarian RM, et al. Surgical management of gallbladder cancer: simple versus extended cholecystectomy and the role of adjuvant therapy. Ann Surg. 2017;266:625–631.
   PubMed Web of Science ®Google Scholar
• Aleksandrova K, Boeing H, Nothlings U, et al. Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer. Hepatology. 2014;60:858–871.
   PubMed Web of Science ®Google Scholar
• Muszynska C, Lundgren L, Lindell G, et al. Predictors of incidental gallbladder cancer in patients undergoing cholecystectomy for benign gallbladder disease: results from a population-based gallstone surgery registry. Surgery. 2017;162:256–263.
   PubMed Web of Science ®Google Scholar
• Baez S, Tsuchiya Y, Calvo A, et al. Genetic variants involved in gallstone formation and capsaicin metabolism, and the risk of gallbladder cancer in Chilean women. World J Gastroenterol. 2010;16:372–378.
   PubMed Web of Science ®Google Scholar
• Harper JW, Elledge SJ. The DNA damage response: ten years after. Mol Cell. 2007;28:739–745.
   PubMed Web of Science ®Google Scholar
• Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009;461:1071–1078.
   PubMed Web of Science ®Google Scholar
• Kinner A, Wu W, Staudt C, et al. Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res. 2008;36:5678–5694.
   PubMed Web of Science ®Google Scholar
• Dent P, Tang Y, Yacoub A, et al. CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle. Mol Interv. 2011;11:133–140.
   PubMedGoogle Scholar
• Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell. 2003;3:421–429.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liu Y, Duan J, et al. Hippocalcin-like 1 suppresses hepatocellular carcinoma progression by promoting p21(Waf/Cip1) stabilization by activating the ERK1/2-MAPK pathway. Hepatology. 2016;63:880–897.
   PubMed Web of Science ®Google Scholar
• Kory N, Grond S, Kamat SS, et al. Mice lacking lipid droplet-associated hydrolase, a gene linked to human prostate cancer, have normal cholesterol ester metabolism. J Lipid Res. 2017;58:226–235.
   PubMed Web of Science ®Google Scholar
• Stopsack KH, Gerke TA, Sinnott JA, et al. Cholesterol metabolism and prostate cancer lethality. Cancer Res. 2016;76:4785–4790.
   PubMed Web of Science ®Google Scholar
• McDonnell DP, Park S, Goulet MT, et al. Obesity, cholesterol metabolism, and breast cancer pathogenesis. Cancer Res. 2014;74:4976–4982.
   PubMed Web of Science ®Google Scholar
• Warner M, Gustafsson JA. On estrogen, cholesterol metabolism, and breast cancer. N Engl J Med. 2014;370:572–573.
   PubMed Web of Science ®Google Scholar
• Di Ciaula A, Wang DQ, Garruti G, et al. Therapeutic reflections in cholesterol homeostasis and gallstone disease: a review. Curr Med Chem. 2014;21:1435–1447.
   PubMed Web of Science ®Google Scholar
• Rai R, Tewari M, Kumar M, et al. Expression profile of cholecystokinin type-A receptor in gallbladder cancer and gallstone disease. Hepatobiliary Pancreat Dis Int. 2011;10:408–414.
   PubMed Web of Science ®Google Scholar
• Trevino F, Carter O. Gallstone size and the risk of gallbladder cancer. JAMA. 1984;251:3080–3081.
   PubMed Web of Science ®Google Scholar
• Lu M, Hu XH, Li Q, et al. A specific cholesterol metabolic pathway is established in a subset of HCCs for tumor growth. J Mol Cell Biol. 2013;5:404–415.
   PubMed Web of Science ®Google Scholar
• Baandrup L, Dehlendorff C, Friis S, et al. Statin use and risk for ovarian cancer: a Danish nationwide case-control study. Br J Cancer. 2015;112:157–161.
   PubMed Web of Science ®Google Scholar
• Bockorny B, Dasanu CA. HMG-CoA reductase inhibitors as adjuvant treatment for hematologic malignancies: what is the current evidence? Ann Hematol. 2015;94:1–12.
   PubMed Web of Science ®Google Scholar
• Mayor S. Statin use is associated with lower risk of liver cancer, study shows. BMJ. 2015;350:h1034.
   PubMedGoogle Scholar
• Wu BU, Chang J, Jeon CY, et al. Impact of statin use on survival in patients undergoing resection for early-stage pancreatic cancer. Am J Gastroenterol. 2015;110:1233–1239.
   PubMed Web of Science ®Google Scholar
• Liu ZW, Alsaggaf R, McGlynn KA, et al. Statin use and reduced risk of biliary tract cancers in the UK clinical practice research datalink. Gut. 2019;68:1458–1464.
   PubMed Web of Science ®Google Scholar
• Moon SH, Huang CH, Houlihan SL, et al. p53 represses the mevalonate pathway to mediate tumor suppression. Cell. 2019;176:564–580 e19.
   PubMed Web of Science ®Google Scholar
• Dang CV. MYC on the path to cancer. Cell. 2012;149:22–35.
   PubMed Web of Science ®Google Scholar
• Hsieh AL, Walton ZE, Altman BJ, et al. MYC and metabolism on the path to cancer. Semin Cell Dev Biol. 2015;43:11–21.
   PubMed Web of Science ®Google Scholar
• Nevins JR. The Rb/E2F pathway and cancer. Hum Mol Genet. 2001;10:699–703.
   PubMed Web of Science ®Google Scholar
• Guerrero-Zotano A, Mayer IA, Arteaga CL. PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment. Cancer Metastasis Rev. 2016;35:515–524.
   PubMed Web of Science ®Google Scholar
• Karki R, Man SM, Malireddi RK, et al. NLRC3 is an inhibitory sensor of PI3K-mTOR pathways in cancer. Nature. 2016.
   Web of Science ®Google Scholar
• Ali A, Levantini E, Fhu CW, et al. CAV1-GLUT3 signaling is important for cellular energy and can be targeted by Atorvastatin in non-small cell lung cancer. Theranostics. 2019;9:6157–6174.
   PubMed Web of Science ®Google Scholar
• Sethunath V, Hu H, De Angelis C, et al. Targeting the mevalonate pathway to overcome acquired anti-HER2 treatment resistance in breast cancer. Mol Cancer Res. 2019.
   PubMed Web of Science ®Google Scholar